MoonLake Immunotherapeutics (MLTX)

NASDAQ: MLTX · Real-Time Price · USD
9.43
+0.77 (8.83%)
Oct 7, 2025, 3:09 PM EDT - Market open
8.83%
Market Cap598.50M
Revenue (ttm)n/a
Net Income (ttm)-176.16M
Shares Out 63.50M
EPS (ttm)-2.79
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume13,441,549
Open8.63
Previous Close8.66
Day's Range8.18 - 9.48
52-Week Range5.95 - 62.75
Beta1.10
AnalystsBuy
Price Target37.63 (+299.26%)
Earnings DateNov 6, 2025

About MLTX

MoonLake Immunotherapeutics, a clinical stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2021
Employees 100
Stock Exchange NASDAQ
Ticker Symbol MLTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Summary

According to 9 analysts, the average rating for MLTX stock is "Buy." The 12-month stock price target is $37.63, which is an increase of 299.26% from the latest price.

Price Target
$37.63
(299.26% upside)
Analyst Consensus: Buy
Stock Forecasts

News

MLTX Investors Have Opportunity to Join MoonLake Immunotherapeutics Fraud Investigation with the Schall Law Firm

LOS ANGELES , Oct. 6, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MoonLake Immunotherap...

18 hours ago - PRNewsWire

MoonLake Immunotherapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - MLTX

LOS ANGELES , Oct. 6, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of MoonLake Immunotherapeutics ("MoonLake" or "the Company") (NASDAQ: MLTX...

18 hours ago - PRNewsWire

MoonLake Immunotherapeutics Investors Should Contact Block & Leviton to Find Out How They Might Recover Losses Through The Firm's Investigation

BOSTON, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Block & Leviton is investigating MoonLake Immunotherapeutics (Nasdaq: MLTX) for potential securities law violations. Investors who have lost money in their Mo...

1 day ago - GlobeNewsWire

MLTX SHAREHOLDER NOTICE: MoonLake Immunotherapeutics Investigated for Securities Fraud after 90% Stock Drop – Contact BFA Law

NEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm  Bleichmar Fonti & Auld LLP announces an investigation into MoonLake Immunotherapeutics (NASDAQ: MLTX) for potential violations ...

1 day ago - GlobeNewsWire

Top 3 Health Care Stocks That Are Preparing To Pump In Q4

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Other symbols: CRVLHRMY
1 day ago - Benzinga

MLTX INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner  James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In MoonLake To Contact Him Directly To Discuss Their Options

1 day ago - GlobeNewsWire

MLTX LEGAL NOTICE: MoonLake Immunotherapeutics Faces Securities Fraud Investigation due to Drug Trial Results – Contact BFA Law if You Lost Money

NEW YORK, Oct. 04, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm  Bleichmar Fonti & Auld LLP announces an investigation into MoonLake Immunotherapeutics (NASDAQ: MLTX) for potential violations ...

3 days ago - GlobeNewsWire

MoonLake Immunotherapeutics (MLTX) Faces Investor Scrutiny After Reporting Disappointing Phase 3 Trial Data For Lead Drug Candidate -- Hagens Berman

SAN FRANCISCO, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Investors in MoonLake Immunotherapeutics (NASDAQ: MLTX) saw the price of their shares crater $55.75, or about 90%, after the company announced disastro...

4 days ago - GlobeNewsWire

MLTX Investors Have Opportunity to Join MoonLake Immunotherapeutics Fraud Investigation with the Schall Law Firm

LOS ANGELES , Oct. 2, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MoonLake Immunotherap...

5 days ago - PRNewsWire

MoonLake Immunotherapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - MLTX

LOS ANGELES , Oct. 2, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of MoonLake Immunotherapeutics ("MoonLake" or "the Company") (NASDAQ: MLTX...

5 days ago - PRNewsWire

MoonLake Immunotherapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – MLTX

LOS ANGELES--(BUSINESS WIRE)--MoonLake Immunotherapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – MLTX.

6 days ago - Business Wire

MLTX BREAKING NEWS: BFA Law is Investigating MoonLake Immunotherapeutics (NASDAQ: MLTX) for Securities Fraud after Stock Drops 90% on Drug Trial Results, Investors Urged to Contact the Firm

NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into MoonLake Immunotherapeutics (NASDAQ: MLTX) for potential violations ...

7 days ago - GlobeNewsWire

MoonLake Immunotherapeutics - Special Call

MoonLake Immunotherapeutics - Special Call Company Participants Matthias Bodenstedt - Chief Financial Officer Jorge da Silva - Co-Founder, CEO & Director Kristian Reich Conference Call Participants Al...

7 days ago - Seeking Alpha

MoonLake Immunotherapeutics Stock Plummets After Phase 3 Data Readouts

MoonLake Immunotherapeutics‘ (NASDAQ: MLTX) stock price fell off a cliff Monday after it reported week-16 results from its Phase 3 VELA-1 and VELA-2 trials.

8 days ago - Benzinga

BREAKING: MoonLake Immunotherapeutics Shares Down Over 85%; Investors Should Contact Block & Leviton to Potentially Recover Losses

BOSTON, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Block & Leviton is investigating MoonLake Immunotherapeutics (Nasdaq: MLTX) for potential securities law violations.

8 days ago - GlobeNewsWire

Moonlake: What's Happening With MLTX Stock?

MoonLake Immunotherapeutics (NASDAQ: MLTX), a biopharmaceutical firm in the clinical stage, experienced substantial fluctuations last week. The stock climbed 10% on Friday, September 26, as investors ...

8 days ago - Forbes

MoonLake shares crash 88% after mixed trial results raise doubts over skin drug

Shares of Swiss biotech MoonLake Immunotherapeutics tumbled 88% to $7.45 in premarket trading on Monday after the company reported mixed outcomes from two late-stage trials of its experimental skin dr...

8 days ago - Invezz

Inventiva, MoonLake Immunotherapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session

U.S. stock futures were higher this morning, with the Dow futures gaining more than 100 points on Monday.

Other symbols: IVA
8 days ago - Benzinga

MoonLake Immunotherapeutics reports on week 16 results of the VELA Phase 3 hidradenitis suppurativa program with the Nanobody® sonelokimab

VELA-1 and VELA-2 are two identical trials to evaluate the efficacy and safety of sonelokimab in adult participants with moderate to severe hidradenitis suppurativa (HS) and the first Phase 3 program ...

9 days ago - GlobeNewsWire

2 Logical Mid-Cap Biotech Buyout Targets

There have been some significant acquisitions in the mid-cap biotech space over the past couple of months. In today's column, I highlight two mid-cap biotech names that should have bright futures on t...

Other symbols: ABVX
5 weeks ago - Seeking Alpha

MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update

ZUG, Switzerland, August 5, 2025 – MoonLake Immunotherapeutics (NASDAQ:MLTX) (“MoonLake” or the “Company”), a clinical-stage biotechnology company focused on creating next-level therapies for inflamma...

2 months ago - GlobeNewsWire

MoonLake Immunotherapeutics: More Sonelokimab Success, With Big Pharma Interest

MoonLake Immunotherapeutics completed enrollment of the two phase 3 VELA studies using Sonelokimab for the treatment of patients with hidradenitis suppurativa. The global psoriatic arthritis market is...

4 months ago - Seeking Alpha

Merck held talks to buy biotech MoonLake for over $3 billion, FT reports

Merck has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than $3 billion, the Financial Times reported on Monday, citing three people familiar with the matter.

Other symbols: MRK
4 months ago - Reuters

MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update

MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update Continued to make significant progress with the development of the Nanobody ® sonelokimab across...

5 months ago - GlobeNewsWire

MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29

MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29 Zug, Switzerland, April 25, 2025 – MoonLake Immunotherapeutics (Nasdaq: MLTX), a clinical-stage biotechnology company foc...

5 months ago - GlobeNewsWire